Antibody Drug Conjugates Market, 2012-2023

Roots Analysis - May 31, 2013 - 145 Pages - SKU: ROAL5058425
Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics. These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology. This class of biologics is attracting the attention of drug developers, with several large and small companies entering the market through collaboration and licensing agreements with technology providers.

The ADC market is still in its infancy. So far, three ADCs have received market approval. However, the first ADC, Mylotarg, was withdrawn from the market by its developer Pfizer. As such, there are only two marketed drugs in 2013. During ... read the full abstract




More Biologics reports by Roots Analysis

Bolus Injectors Market, 2014-2024 by Roots Analysis
Bolus Injectors Market, 2014-2024 The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to ...
Bispecific Antibody Therapeutics Market, 2013-2023 by Roots Analysis
INTRODUCTION Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the ...
See all reports like this >>

Since 1998, MarketResearch.com has provided companies with the business intelligence and research they need to make informed decisions.

We provide information on products, trends, regions, demographics, industries and companies from our collection of over 700 research publishers and 400,000 research reports.

About Us
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!